Luo Yongwen, Li Junli, Liu Zhifen, Yu Heping, Peng Xiang, Cao Cheng'an
Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Institute of Laboratory Animal Sciences, Peking Union Medical College, Beijing, China.
PeerJ. 2020 Nov 26;8:e10459. doi: 10.7717/peerj.10459. eCollection 2020.
The coronavirus 19 (COVID-19) pandemic has heightened the threat to the health and lives of patients with comorbid diseases. Infection by COVID-19 is especially detrimental to patients on hemodialysis. In this study, we evaluated the clinical characteristics, laboratory findings, treatments and prognoses of hemodialysis patients with COVID-19.
A total of 16 hemodialysis patients with COVID-19 were recruited from Wuhan Fourth Hospital from 5 February to 20 March 2020 for a retrospective, single-center study. A total of 62 non-dialysis patients with COVID-19 were the control group. We collected data on the clinical characteristics, laboratory findings, treatments, and clinical outcomes of patients affected by the virus.
Hemodialysis patients with COVID-19 had a lower incidence of fever ( = 0.001) and relatively higher incidence of pre-admission comorbidities and shortness of breath than non-dialysis patients with COVID-19 (75% vs. 61%, = 0.467 50% vs. 33.87%, = 0.248 ). Hemodialysis patients had lower levels of hemoglobin ( < 0.001), white blood cell counts ( = 0.015), neutrophils ( = 0.016), AST ( = 0.037), ALT ( < 0.001) and procalcitonin ( < 0.001), and higher levels of D-dimer ( < 0.001) and thrombin time ( < 0.001). Hemodialysis patients had a higher incidence of pulmonary effusion, cord-like high-density shadows, pleural thickening, and atelectasis ( < 0.05). Hemodialysis patients also had relatively higher rates of mortality and prolonged hospital stays compared with the control group.
Hemodialysis patients typically present with multiple comorbidities and are considered to be a high-risk group for COVID-19 infections. Hemodialysis patients with COVID-19 may have prolonged hospital stays and unfavorable prognoses and should be closely monitored.
新型冠状病毒肺炎（COVID-19）大流行加剧了对合并症患者健康和生命的威胁。COVID-19感染对血液透析患者尤其有害。在本研究中，我们评估了COVID-19血液透析患者的临床特征、实验室检查结果、治疗方法和预后。
2020年2月5日至3月20日，从武汉第四医院招募了16例COVID-19血液透析患者进行回顾性单中心研究。共有62例非透析COVID-19患者作为对照组。我们收集了受该病毒影响患者的临床特征、实验室检查结果、治疗方法和临床结局的数据。
与非透析COVID-19患者相比，COVID-19血液透析患者发热发生率较低（P = 0.001），入院前合并症和呼吸急促发生率相对较高（75%对61%，P = 0.467；50%对33.87%，P = 0.248）。血液透析患者血红蛋白水平较低（P < 0.001）、白细胞计数（P = 0.015）、中性粒细胞（P = 0.016）、谷草转氨酶（P = 0.037）、谷丙转氨酶（P < 0.001）和降钙素原（P < 0.
